Categories Navigation

Asset Publisher

null HIV and STD Unit, Infectious Disease Service
Hospital Universitario de Bellvitge (Barcelona)


Our HIV and STD Unit have been involved in the management of HIV-infected patients since 1985. During all these years, we have acquired a vast experience in diagnosing and treating HIV and its complications. We participated and organized hundreds of national and international clinical trials regarding multiple aspects such as efficacy and tolerability of antiretroviral therapy, opportunistic infections and others. In addition to CORIS, we participate in the PISCIS cohort and through it in international cohorts such as COHERE (Collaboration of Observational HIV Epidemiological Research in Europe) and ART-CC (Antiretroviral Therapy Cohort Collaboration).

We have also participated in several expert panels for the Guidelines of management of opportunistic infections (NIH/CDC/IDSA), antiretroviral therapy (GESIDA), opportunistic infections (GESIDA), and neurocognitive disorders (GESIDA)

Our main areas of research are:

  • Antiretroviral therapy.  Phase II-IV studies. Efficacy and tolerability. New compounds. PrEP. For a better knowledge and use of ARV drugs and regimens before and after their approval, including new prevention strategies. 
  • Antiviral activity and pharmacology in viral reservoirs such as genital compartments and cerebrospinal fluid. To understand the role of different ARV compounds in viral “sanctuaries”: trying to prevent and treat neurocognitive disorders and reduce sexual transmission of HIV
  • Cardiovascular risk in HIV patients. A frequent complication of HIV infected patients related to traditional CVR factors, inflammation and drug toxicity.
  • Neurocognitive disorders secondary to HIV infection. CNS is a target of HIV since the beginning of the viral entry.
  • Human Papilloma Virus infection and prevention of anal cancer. A frequent infection which may lead to severe complications such as anal cancer.  
  • Sexually transmitted diseases, diagnosis and treatment. A new and growing epidemic in HIV-infected patients mainly in MSM and those engaged in the so called “chemsex”

Our team is composed by 8 physicians/clinical researchers, two nurses, one health care assistant, one psychologist, 3 clinical trials coordinators, one dietitian and 1 statistician. The Unit is located in the 3rd floor building known as Ex- escuela de enfermeria, within the Hospital Universitari de Bellvitge and it is opened from 7.30 to 17.30 hs from Mondays to Fridays.

Related Assets


Daniel Podzamczer
Laura Acerete
Elena Ferrer
Benito García
Dolors Giralt
Arkaitz Imaz
Silvina Magnani
Sandra Morenilla
Antonio Navarro
Jordi Niubó
Sara Rico
Josefa Ruiz
Ana Carina Silva
María Saumoy
Juan Tiraboschi
Josefa Torres
Loris Trenti
Antonia Vila
Cristina Padilla
Camila Piatti
Paula Prieto

Related Assets

Related Assets


  • HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. 
    Imaz A, Martinez-Picado J, Niubó J, Kashuba AD, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczer D.  J Infect Dis. 2016 Nov 15;214(10):1512-1519. 
  • Saumoy M, Alonso-Villaverde C, Navarro A, Olmo M, Vila R, Maria Ramon J, Yacovo SD, Ferrer E, Curto J, Vernet A, Vila A, Podzamczer D  Atherosclerosis. 2016 Volume 246, Pages 301–308 
  • Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status. 
    Ferrer E, Curto J, Esteve A, Miro JM, Tural C, Murillas J, Segura F, Barrufet P, Casabona J, Podzamczer D; PISCIS Investigators.  J Antimicrob Chemother. 2015 Sep 25. pii: dkv272 
  • Maraviroc levels in cerebrospinal fluid in HIV-infected patients. 
    Tiraboschi JM, Curto J, Niubo J, Podzamczer D.  J Acquir Immune Defic Syndr 2010; 55: 606-609. 
  • Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. 
    Podzamczer D, Ferrer E, Sanchez P, Gatell JM, Crespo M, Fisac C, Lonca M, Sanz J, Niubo N, Veloso S, Llibre JM, Barrufet P, Ribas MA, Merino E, Ribera E, MD, Martínez-Lacasa J, Alonso C, Aranda M, Pulido F, Berenguer J, Delegido A, Pedreira JD, Lérida A, Rubio R, del Río L.  JAIDS 2007; 44: 139-147. 
  • Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. 
    Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM and Podzamczer D.  AIDS 2005; 19: 917-925. 
  • Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. 
    Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortes C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM.  N Engl J Med 2003; 349: 1036-1046. 
  • A randomized clinical trial comparing nelfinavir or nevirapine associated to ZDV/3TC in HIV-infected naive patients (The Combine Study). 
    Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, González A, Pedrol E, Lozano L, Ocaña I, Llibre JM, Casiro A, Aranda M, Barrufet P, Martinez Lacasa J, Miró JM, Badía X, Casado A, Lupo S, Cahn P, Maños M, Estela J, and the Combine Study Team.  Antiviral Therapy 2002; 7: 81-90. 
  • A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in HIV infection. 
    Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, Podzamczer D, Alberdi JC, Martinez E, Cosin J, Claramonte X, Gonzalez J, Domingo P, Casado JL, Ribera E, and the Grupo de Estudio del SIDA 04/98.  N Engl J Med 2001; 344: 159-67. 
  • Intermittent trimethoprim-sulfamethoxazole compared with dapsone pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in HIV-infected patients. 
    Podzamczer D, Salazar A, Jiménez J, Consiglio E, Santín M, Casanova A, Rufí G, Gudiol F.  Ann Intern Med 1995; 122: 755-61. 

Related Assets